{"id":1017569,"date":"2026-11-05T09:13:33","date_gmt":"2026-11-05T14:13:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/"},"modified":"2026-11-05T09:13:33","modified_gmt":"2026-11-05T14:13:33","slug":"gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/","title":{"rendered":"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BETHESDA, Md., Nov.  05, 2026  (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two late-breaking posters at the 31<sup>st<\/sup> IAPRD World Congress on Parkinson\u2019s Disease and Related Disorders as well as a poster at Neuroscience 2026.<\/p>\n<p>\n        <strong>31<\/strong><br \/>\n        <sup><br \/>\n          <strong>st<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> IAPRD World Congress on Parkinson\u2019s Disease and Related Disorders<\/strong>\n      <\/p>\n<p>Location: Milan, Italy<\/p>\n<p>Date: November 11-14, 2026<\/p>\n<p>Poster Title: \u201cOpen label extension of a Phase 1b clinical study to evaluate the effect of <em>rexaceract<\/em> (GT-02287) in Parkinson\u2019s Disease\u201d<\/p>\n<p>Presentation Type: Guided Poster Tour<\/p>\n<p>Poster Number: P9.8<\/p>\n<p>Assigned Topic: Late Breakers<\/p>\n<p>Date and Time: 3:30 \u2013 4:30 p.m. CET, November 13<\/p>\n<p>Poster Title: \u201cPreclinical development of the novel GCase allosteric modulator GT-04686 in a GBA1 Parkinson\u2019s disease model\u201d<\/p>\n<p>Presentation Type: Gallery Poster<\/p>\n<p>Poster Number: P17.23<\/p>\n<p>Assigned Topic: Parkinson&#8217;s Disease: Therapy (excluding surgical, physical)<\/p>\n<p>\n        <strong>Neuroscience 2026<\/strong>\n      <\/p>\n<p>Location: Washington, D.C.<\/p>\n<p>Date: November 14-18, 2026<\/p>\n<p>Poster Title: \u201cNovel allosteric GCase modulator GT-04686 reduces neuropathology and improves motor and non-motor function in a preclinical model of GBA1 Parkinson\u2019s disease\u201d<\/p>\n<p>Presentation Type: Poster<\/p>\n<p>Presentation Number: PSTR222.06<\/p>\n<p>Session Title: Parkinson&#8217;s Disease: Therapeutic Strategies in Preclinical Models<\/p>\n<p>Session Date and Time: 8:00 a.m. &#8211; 12:00 p.m. EST, November 17<\/p>\n<p>Presentation Time: 8:00 a.m. &#8211; 9:00 a.m. EST, November 17<\/p>\n<p>\n        <strong>About the International Association of Parkinsonism and Related Disorders (IAPRD)\u2019s 31<\/strong><br \/>\n        <sup><br \/>\n          <strong>st<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> World Congress on Parkinson\u2019s Disease and Related Disorders<\/strong><br \/>\n        <br \/>The IAPRD World Congress provides a collegial atmosphere to meet, interact and network with colleagues from around the world who are interested in the field of parkinsonism and related disorders. IAPRD 2026 will feature a program of clinical and scientific sessions revolving around the theme <em>Enhancing Patient Care Through Education, Technology, and Therapeutics.<\/em> A global faculty of distinguished experts will provide updates on the latest developments, current knowledge, and new tools enabling innovative research and treatment in parkinsonism and related disorders.<\/p>\n<p>\n        <strong>About the SfN (Society for Neuroscience) \u2019s Neuroscience 2026 Annual Meeting<\/strong><br \/>\n        <br \/>The SfN annual meeting brings together scientists from around the world to discover new ideas, share their research, and experience the best the neuroscience field has to offer. Neuroscience 2026 will feature lectures, symposia, and events for scientists at all career stages.<\/p>\n<p>\n        <strong>About Gain Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain\u2019s lead drug candidate, <em>rexaceract<\/em> is currently being evaluated for the treatment of PD with or without a GBA1 mutation in a Phase 1b clinical trial. <em>Rexaceract<\/em> has further potential in Gaucher\u2019s disease, dementia with Lewy bodies, and Alzheimer\u2019s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.<\/p>\n<p>Gain\u2019s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan\u2122 platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains \u201cforward-looking statements\u201d made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d or similar expressions. These forward-looking statements reflect management\u2019s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company\u2019s current or future product candidates; expectations regarding the timing of patient enrollment and the completion and timing of results from a Phase 1b clinical study for <em>rexaceract<\/em>, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; the timing of the commencement of the Phase 2 clinical study for <em>rexaceract<\/em>; the Company\u2019s ability to enroll patients in its planned Phase 2 clinical study for <em>rexaceract<\/em>; the Company\u2019s ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; the Company\u2019s business development activities, strategic collaborations, licensing opportunities and financing activities; the advancement, prioritization and timing of the Company\u2019s pipeline programs, including GT-04686; and the potential therapeutic and clinical benefits of the Company\u2019s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company\u2019s business in general, please refer to the Company\u2019s Form 10-K for the year ended December 31, 2025, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Gain Therapeutics, Inc.\u00a0<br \/>Apaar Jammu\u00a0<br \/>Director, Investor Relations and Public Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JVJVcKcycja3C8YXwsDoBKjuNNqPOabAMjyPBhd-o-NAyjUP1R6SkwQpXfHwXXoydtyzlCBWAXX1fv8xo6c-jBxv-mhwnP97wR9WsxdaHoLt5SLjVOql31rEvGU85djJr-0TZVTww95-vmB8HkSYT3T8U2iVa4cZJPQ1J5YyWQB1_VD1m1EenEBTYhcXhdfr-N-yk6LUO_QGrHve0eg73bPh8Bi7e8PtenQ51sIOhV0cmHcZtRsMytQrFld0dZwY3c0LYx70QJCl9qiudjb30PZ2l7bXEz9CaRAlG48wQNnuQaPly7-gdU7nihkEQT3Nc1kYsJnoUbTEVs7959ctCe4ygS8gAHkXH64jDbPxCYa4a-RxQJrxibfujBJlCzMnySHTaJgC3q9KldKr_MleyEFGTMZQh4zFh8EnOEQhWcRTJlC8fJoeAI_JFXo2hpWEAB3J3v7AP94FxvTMSgRf2lCzMeymMfShC09Ib5tAFhACEfDbm97Nhrlt7LWeQhe_w7nZMjMzZoHGcqpFQWKf7REv5k6jwz8glzSevjYinLyA-M60SxiQM1aXOWqv7LQ0fy0mL0O2fCcXKz9Bazcx0c5YV1bd4tzLAT2DSMyAd56phuYJXnlAV2PCSTy0MgUrlV1Q2xiVD5DC0o8-r3DsQxzmlC4F3OUiOyuonLmrcqONcSO3BCW7k4kalEo6wXmX7CXEkLu6_98lK_s9huQsg16WVw7Cs098BE1rG3V6GeprimRVf-x_-H1Uqhh_GyiYtLEhFVg36dx2Xbe0COt9Xt-2UZgUyolLoMjAQr-IqbUKvmxWuTwU_50AVJiqaqj7qUqOma2hzTh-UHM6tYZmSg==\" rel=\"nofollow\" target=\"_blank\"><u>ajammu@gaintherapeutics.com<\/u><\/a><\/p>\n<p>LifeSci Advisors LLC<br \/>Chuck Padala<br \/>Managing Director<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oudtbTmMJZo7nHajQJPAUhI_J57bQOuftRHLCsv1YEulPqM79V_3PtkaLj4O5Tm1WHx5yxJofj9SqFGn7dAFSXKksB7uNHxZ5CSFOZo7ZqWKAJE2o0ilUXLacS3LJGyhLr5Nvuw9sI9e3a6OJ01pRtwh4ntj2n4zdQp1Tkp3CwrbCoYWIVHgZ6TCCBLLtzzRzjrUhoUZ9Va-u_Y246FgLGvtosyriaYSkqu-DjcQEmffvYYj_lsGBzhY8fEszxZ72Rforofz9lZwxQ1AVbRkU9mjoVw14VrCBvp-ok1ITJJRNIzNvDfqhBDIBwCijGR2Q8CBEI56pI8JautOz3iuT4La9ghWRlBfvn2bIDwogCol1AGjQFeh9r7HE_j8lvsoLAdwBYFxOmEG-Oo1thPZIsdINe94F4U-d7uW08gJby0PWw09dTnrSxBjz3OPHyjuWzfGlNieKTsWRCUGsHs-LDRBNG4GIqO3J1cqddlPzJNnCiZbB-2N5if03j_2JQVBmYd6ThaE9-fUwvFeBG8XadMTPXzING2kvOHudgFkGa8wvezUlHNDus7QNx7i98g17_fv-e9qXMPtetqffg_G6FTg2XgdJqjxBNiazLeNxeOpwnD5QPAb_obEfQ_pO5vaWePBKsbcrPcFZ0g3_O0463YbiolpPVII7kngAkSL0KEPCvF9TRU_prl5_V0YnCDGKMaZPLojIb-1rqVQ1znfW8W8rR_JlrKup4bUPAPUohPqlESBaTQ8PiIi6qj6t_9nF30a53DMtsrt6cDXLYh-Wz7hoFLqfO1-RFsnQP8BEj7vsxvCGILHL8UfW7ie44PWNdV4I_S5oco7mC1DNzxFBQ==\" rel=\"nofollow\" target=\"_blank\"><u>chuck@lifesciadvisors.com<\/u><\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Russo Partners LLC <br \/>Nic Johnson and Elio Ambrosio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uYBpYJPqPqUAZ5efevxS906qk-wgzOeKhfrJsuwGADV2Tt9U5rR6lzASp7vXxB0Y_9YeNjvnct_zM2rBrefR1E8ttqelaf2QQnM40RMxHSxc7kk7Ubb67wgfAVd2bZDy7HcPMiQstnQsM08JxYsNNg==\" rel=\"nofollow\" target=\"_blank\"><u>nic.johnson@russopartnersllc.com<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1iTNkmZYBMIiZfKIW5fK8arE_Gsa2HDPgXxozHf3YWjet2mBS7mt6bi1EIK7DFWpOFObZX2xSE2SEGJ5Wun5PKfFvL6l69FSOWg--JWkHVllDVor4JdyykAA3Lby_NJPZoL3Bjxt6CvctZQ6oKXxNA==\" rel=\"nofollow\" target=\"_blank\"><u>elio.ambrosio@russopartnersllc.com<\/u><\/a><br \/>(760) 846-9256<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTljN2RlYWEtNmIyMC00MjgxLWE3NWUtZTY2MjhmZDI0N2YxLTEyMjA1ODMtMjAyNi0xMS0wNS1lbg==\/tiny\/Gain-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two late-breaking posters at the 31st IAPRD World Congress on Parkinson\u2019s Disease and Related Disorders as well as a poster at Neuroscience 2026. 31 st IAPRD World Congress on Parkinson\u2019s Disease and Related Disorders Location: Milan, Italy Date: November 11-14, 2026 Poster Title: \u201cOpen label extension of a Phase 1b clinical study to evaluate the effect of rexaceract (GT-02287) in Parkinson\u2019s Disease\u201d Presentation Type: Guided Poster Tour Poster Number: P9.8 Assigned Topic: Late Breakers Date and Time: 3:30 \u2013 4:30 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1017569","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two late-breaking posters at the 31st IAPRD World Congress on Parkinson\u2019s Disease and Related Disorders as well as a poster at Neuroscience 2026. 31 st IAPRD World Congress on Parkinson\u2019s Disease and Related Disorders Location: Milan, Italy Date: November 11-14, 2026 Poster Title: \u201cOpen label extension of a Phase 1b clinical study to evaluate the effect of rexaceract (GT-02287) in Parkinson\u2019s Disease\u201d Presentation Type: Guided Poster Tour Poster Number: P9.8 Assigned Topic: Late Breakers Date and Time: 3:30 \u2013 4:30 &hellip; Continue reading &quot;Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-05T14:13:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences\",\"datePublished\":\"2026-11-05T14:13:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/\"},\"wordCount\":935,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/\",\"name\":\"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=\",\"datePublished\":\"2026-11-05T14:13:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences - Market Newsdesk","og_description":"BETHESDA, Md., Nov. 05, 2026 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the presentation of two late-breaking posters at the 31st IAPRD World Congress on Parkinson\u2019s Disease and Related Disorders as well as a poster at Neuroscience 2026. 31 st IAPRD World Congress on Parkinson\u2019s Disease and Related Disorders Location: Milan, Italy Date: November 11-14, 2026 Poster Title: \u201cOpen label extension of a Phase 1b clinical study to evaluate the effect of rexaceract (GT-02287) in Parkinson\u2019s Disease\u201d Presentation Type: Guided Poster Tour Poster Number: P9.8 Assigned Topic: Late Breakers Date and Time: 3:30 \u2013 4:30 &hellip; Continue reading \"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-05T14:13:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences","datePublished":"2026-11-05T14:13:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/"},"wordCount":935,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/","name":"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=","datePublished":"2026-11-05T14:13:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3MDg2OCM3OTQ3NjMzIzIyMDkwMzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-announces-late-breakers-and-poster-presentations-at-upcoming-scientific-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1017569"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1017569\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1017569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1017569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1017569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}